002675.SZ
东诚药业
SZSE · Healthcare · C 制造业 · CN
CNY 12.77
−2.07%Sep 2, 2026, 09:03 UTC
Dongcheng Pharmaceutical announced that as of August 31, 2026, it had repurchased 7.3995 million shares (0.90% of total shares) for a total of 100 million yuan under its ongoing buyback program.
Source:Aug 24, 2026, 10:35 UTC
Dongcheng Pharmaceutical's wholly-owned subsidiary Andike signed equity transfer agreements to acquire 100% of Kunming Cyclotron and 100% of Sichuan Cyclotron for RMB 40.2 million and RMB 40 million respectively, and to sell its 45% stake in Guangdong Cyclotron for RMB 121 million.
Source:Aug 14, 2026, 08:15 UTC
Dongcheng Pharmaceutical's subsidiary Andike received a radioactive drug production license from Shanxi Provincial Drug Administration, allowing its Shanxi Jinzhong nuclear medicine production center to begin operations, producing fludeoxyglucose F-18 injection.
Source:Aug 6, 2026, 11:55 UTC
Dongcheng Pharmaceutical announced that its marketing application for the API bemiparin sodium has been accepted by the National Medical Products Administration.
Source: